company background image
RVNC logo

Revance Therapeutics NasdaqGM:RVNC Stock Report

Last Price

US$3.61

Market Cap

US$378.7m

7D

-5.0%

1Y

-51.4%

Updated

02 Dec, 2024

Data

Company Financials +

Revance Therapeutics, Inc.

NasdaqGM:RVNC Stock Report

Market Cap: US$378.7m

RVNC Stock Overview

A biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. More details

RVNC fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Revance Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Revance Therapeutics
Historical stock prices
Current Share PriceUS$3.61
52 Week HighUS$9.75
52 Week LowUS$2.30
Beta0.95
11 Month Change-37.76%
3 Month Change-45.22%
1 Year Change-51.41%
33 Year Change-75.24%
5 Year Change-77.73%
Change since IPO-86.55%

Recent News & Updates

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Sep 26

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Jun 20

Recent updates

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Sep 26

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Jun 20

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Mar 04
What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Feb 29

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28
Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Nov 10
Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Aug 10
Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Jun 14
Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Apr 17
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Jan 02
Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Revance Therapeutics submits sBLA for Daxxify for cervical dystonia

Oct 20

Revance climbs 14% as FDA approves facial injectable for frown lines

Sep 08

Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems

Aug 24

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Aug 04
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Shareholder Returns

RVNCUS PharmaceuticalsUS Market
7D-5.0%1.9%0.6%
1Y-51.4%12.4%31.9%

Return vs Industry: RVNC underperformed the US Pharmaceuticals industry which returned 12.4% over the past year.

Return vs Market: RVNC underperformed the US Market which returned 31.9% over the past year.

Price Volatility

Is RVNC's price volatile compared to industry and market?
RVNC volatility
RVNC Average Weekly Movement15.2%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement6.3%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: RVNC's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RVNC's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1999597Mark Foleywww.revance.com

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage.

Revance Therapeutics, Inc. Fundamentals Summary

How do Revance Therapeutics's earnings and revenue compare to its market cap?
RVNC fundamental statistics
Market capUS$378.70m
Earnings (TTM)-US$303.01m
Revenue (TTM)US$256.95m

1.5x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RVNC income statement (TTM)
RevenueUS$256.95m
Cost of RevenueUS$153.26m
Gross ProfitUS$103.69m
Other ExpensesUS$406.70m
Earnings-US$303.01m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.89
Gross Margin40.35%
Net Profit Margin-117.93%
Debt/Equity Ratio-264.5%

How did RVNC perform over the long term?

See historical performance and comparison